Overview
Employees
11-50
Founded date
2004
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 15, 2024 | Oncolys Biopharma presents a business report on the oncolytic virus “Telomerysin” and “OBP-601”, which is being developed for intractable neurological diseases (PSP, ALS, etc.) (Interim financial results briefing for the fiscal year ending December 2 | Oncolys Biopharma presents a business report on the oncolytic virus “Telomerysin” and “OBP-601”, which is being developed for intractable neurological diseases (PSP, ALS, etc.) (Interim financial results briefing for the fiscal year ending ... |
| Aug 15, 2024 | Oncolys Biopharma presents a business report on the oncolytic virus “Telomerysin” and “OBP-601”, which is being developed for intractable neurological diseases (PSP, ALS, etc.) (Interim financial results briefing for the fiscal year ending December 2 | |
| Feb 10, 2022 | Oncolys BioPharma : Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2021 | NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations. Non-consolidated Financial Results for the Fiscal Year Ended December 31, 2021 [Japanese... |
| Dec 7, 2021 | Oncolys BioPharma : First Patient Dosed in NRG Oncology Phase I Clinical Trial for Telomelysin(OBP-301)-Chemoradiation Combination Therapy for Esophageal Cancer Patients | Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. December 7, 2021 Oncolys... |
| Nov 5, 2021 | Non-consolidated Financial Results for the Nine Months Ended September 30, 2021 [Japanese GAAP] | Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. Non-consolidated Financi... |
| May 6, 2021 | ONCOLYS BIOPHARMA INC. Oncolys BioPharma : Announcement of First Patient Enrolled in Oncology Investigator-Initiated Phase 2 Clinical Trial for Telomelysin (OBP-301) of Head and Neck Cancer | NB: this is a summary translation of the press release original drafted in Japanese for the disclosure May 6, 2021 required in compliance with the TSE regulations. Oncolys BioPharma Inc. Announcement of First Patient Enrolled in Oncology In... |
| Jun 22, 2007 | Tacere Therapeutics sells equity stake to Oncolys BioPharma for hepatitis-drug development | Tacere Therapeutics, a San Jose, Calif., biotech developing new RNA-based drugs, struck a partnership with Tokyo’s Oncolys BioPharma to co-develop a treatment for hepatitis C. The companies didn’t disclose financial terms of the deal. In ex... |
Reviews 0
FAQ about Oncolys BioPharma Inc.
When was Oncolys BioPharma Inc. founded?
Oncolys BioPharma Inc. was founded in 2004.
What has the press written about Oncolys BioPharma Inc.?
Parsers VC has collected 8 articles mentioning Oncolys BioPharma Inc., among them “Oncolys Biopharma presents a business report on the oncolytic virus “Telomerysin” and “OBP-601”, which is being developed for intractable neurological diseas...” (Aug 15, 2024) and “Oncolys Biopharma presents a business report on the oncolytic virus “Telomerysin” and “OBP-601”, which is being developed for intractable neurological diseas...” (Aug 15, 2024).
Is Oncolys BioPharma Inc. still active?
Yes, Oncolys BioPharma Inc. is active; its latest activity on Parsers VC dates from Aug 27, 2026.